Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.01 price target on the stock.
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025GlobeNewswire
- Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswire
- Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.MarketBeat
- Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaGlobeNewswire
BCAX
Sec Filings
- 3/18/25 - Form 4
- 3/14/25 - Form 144
- BCAX's page on the SEC website